<DOC>
	<DOCNO>NCT00575406</DOCNO>
	<brief_summary>Diffuse large B-cell lymphoma prevalent subgroup within malignant lymphoma . Clinical benefit show treatment cyclophosphamide , doxorubicin , vincristin prednisolone ( CHOP regimen ) ; could improve recently addition rituximab ( R-CHOP ) , monoclonal antibody . Improved response overall survival rate make necessary evaluate late toxicity therapy regimen . Cardiotoxicity know risk factor specific chemotherapy , 7 % patient affected doxorubicin cumulative dos 550mg/sqm . Retrospective data analysis indicate incidence cardiotoxicity may higher combination chemotherapy . Liposomal doxorubicin show low cardiotoxic effect time equivalent high efficacy compare conventional doxorubicin . The aim study evaluate alternative regimen treatment diffuse large B-cell lymphoma , substitute liposomal doxorubicin ( R-COMP ) conventional doxorubicin ( R-CHOP ) .</brief_summary>
	<brief_title>Multicentre Study Determine Cardiotoxicity R-CHOP Compared R-COMP Patients With Diffuse Large B-Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Cardiotoxicity</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Histologically confirm , CD20 positive , diffuse large Bcell lymphoma ( DLCL ) measurable disease accord international criterion male female age 18 year write informed consent myocardial infarction within 6 month prior study entry cardiac insufficiency NYHA grade 3 4 previous treatment chemotherapy radiotherapy CNS involvement disease positive HIV WHO Performance Index 3 4 secondary malignoma concurrent disease prohibit chemotherapy know hypersensitivity towards study intervention constituent neutropenia thrombopenia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>